Scalper1 News
Big-cap biotech and IBD 50 stock Gilead Sciences put an important brick in its fortress against competition Wednesday when it reported positive trial data for its latest HIV drug. Its stock rose 3% to 108.66 on the news. The drug, called tenofovir alafenamide (TAF), has been nicknamed “Son of Viread” by Wall Street because it’s a new and improved version of Gilead’s (GILD) flagship HIV drug Viread. Since Viread first hit the market in 2001, most Scalper1 News
Scalper1 News